TY  - JOUR

T1  - Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

JO  - VALUE IN HEALTH

PY  - 2011/01/01

AU  - Schwenkglenks M

AU  - Brazier JE

AU  - Szucs TD

AU  - Fox KAA

ED  - 

DO  - DOI: 10.1016/j.jval.2010.10.025

VL  - 14

IS  - 1

SP  - 24

EP  - 33

Y2  - 2024/12/22

ER  -